Gregory Bix, MD, PhD, FAHA, Professor of Neurosurgery and Neurology at Tulane University, is also currently the Director of the Clinical Neuroscience Research Center, Vice-Chair of Clinical & Translational Research, Department of Neurosurgery, and the Vada Odom Reynolds Chair in Stroke Research at Tulane University. He also holds the position of Clinical Lecturer (honorary) at the University of Glasgow, adjunct Professor at the Queensland University of Technology, Professor (honorary) at the University of Manchester, and is a Fellow of the American Heart Association. He completed his clinical and research training at Baylor College of Medicine, the University of Pennsylvania, and Thomas Jefferson University. He has published more than 50 papers in reputed journals, won several research awards, and is the inventor on several patents for his various scientific discoveries. Dr. Bix is currently the P.I. on 4 NIH R01 grants, 1 NIH R21 and co-Investigator on two NIH R44 SBIR grants. Dr. Bix’s research focus is in the role and therapeutic potential of the extracellular matrix and its receptors in stroke and vascular dementia.
Dr. Bix is currently studying vascular contributions to cognitive impairment and dementia and the effects of aging in ischemic stroke.
- Bix G,et al Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin. J. Cell Biol. 2004; 166: 97-109.
- Bix G, et al. Endorepellin In Vivo: Targeting the Tumor Vasculature and Retarding Cancer Growth and Metabolism. J. Nat. Canc. Inst. 2006; 98: 1634-1646.
- Lee B... Bix, G. Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in Rodents. JCI. 2011; 121: 3005-23